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Abstract
Normal B lymphocytes as well as malignant B cells extravasate from blood circulation during physiological and pathological processes
and require matrix metalloproteinases (MMPs) to facilitate trafficking through the subendothelial basal lamina and the extracellular matrix.
We have previously shown that Epstein–Barr virus (EBV)-immortalized B lymphocytes constitutively synthesized low levels of MMP-9 and
huge amounts of its preferential inhibitor, tissue inhibitor of matrix metalloproteinase-1 (TIMP-1). In the present study, TIMP-1 phenotypic
expression was extensively investigated in response to various mediators including interleukins, chemokines, growth factors and tumor
promotor, and was compared to MMP-9 synthesis. Results showed a roughly constitutive TIMP-1 expression opposed to an inducible MMP-
9 synthesis. Nevertheless, further analysis of TIMP-1 synthesis showed the existence of regulation mechanisms: modulation of intracellular
Ca2 + concentration as well as cation ionophore monensin were demonstrated to influence TIMP-1 production and secretion. The precise
pathways implicated in these regulation mechanisms are currently under survey. D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
The matrix metalloproteinases (MMPs) constitute a fam-
ily of zinc-endoproteinases initially characterized by their
ability to degrade the components of the extracellular matrix
and basement membrane [1–3]. These enzymes are also
involved in the release of cell surface receptors and signal-
ing factors [4]. MMPs are, in general, rarely expressed in
normal tissues, but are abundant in situations marked by
rapid morphological changes, i.e. wound healing, embryo-
genesis and involution of reproductive tissues, and in
pathological situations marked by tissue destruction such
as inflammatory diseases and cancer. Their activity is
controlled extracellularly by specific enzyme inhibitors,
the tissue inhibitors of matrix metalloproteinase (TIMPs),
of which four forms have been characterized [5–7]. How-
ever, in addition to blocking MMP activity, TIMPs have
been shown to exert growth factor functions that are
independent of their enzymatic inhibitory activity [8–11].
Moreover, TIMP-1, first identified as an erythroid potenti-
ating factor [12,13], is also known to inhibit apoptosis in
different cell lines [14,15] and to induce B cell differ-
entiation [16,17].
Under physiological and some pathological conditions,
MMP and TIMP expression is regulated by different effec-
tors including growth factors, cytokines, steroid hormones
and cellular oncogenes [18,19]. The response to these
factors is not only MMP/TIMP-dependent, but also depends
on the cell type studied.
B lymphocytes are immune cells whose main function
is to produce antibodies in response to stimulation by
foreign antigens. The activation process occurs within the
context of lymphoid organs and requires a continuous
recirculation of lymphocytes between blood and tissues
[20–22]. Crossing basement membrane and migration
through the stroma tissue requires specific tools able to
degrade the extracellular matrix. B cells from different
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origins have been shown to synthesize MMP-2, MMP-9
and TIMP-1 [23,24].
B lymphocytes can be immortalized by Epstein–Barr
virus (EBV) infection leading to the establishment of
lymphoblastoid cell lines. EBV that infects the vast majority
of humans is associated with an expanding number of
neoplastic diseases including Burkitt’s lymphoma and
Hodgkin’s disease, many of which progress to highly
malignant lymphomas [25,26].
As MMPs and TIMPs are implicated in tumor invasion
and metastasis, especially in Burkitt’s lymphoma and neo-
plastic B cell lines [27,28], we chose to study expression of
MMPs and TIMPs by EBV-immortalized B lymphocytes,
which may be considered as premalignant cell lines. We
have previously shown that EBV B cells are able to
constitutively secrete MMP-9 (gelatinase B, 92-kDa type
IV collagenase, EC 3.4.24.35) and its preferential inhibitor
TIMP-1 [29]. Moreover, MMP-9 expression was demon-
strated to be finely regulated by various physiological
mediators. We examined here the regulation of TIMP-1
synthesis by EBV B lymphocytes and compared it to the
MMP-9 expression pattern. Several types of mediators were
chosen according to their involvement in B cell differ-
entiation (interleukins IL-1h, IL-2, IL-6), in Burkitt’s lym-
phomas (IL-1h, IL-6, IL-10) [30–32] or in EBV-induced
tumorigenesis [33]. IL-10 is known to abolish angiogenesis
and tumorigenicity of Burkitt’s lymphoma cells [34], and
retinoic acid is described as a powerful inhibitor of EBV B
lymphocyte growth [35]. Other agents (TNFa, lipopolysac-
charide (LPS), concanavalin A (Con A), etc.) are mediators
of infectious or inflammatory situations. The results showed
that TIMP-1 production is broadly constitutive whereas
MMP-9 synthesis is inducible and highly controlled. More-
over, intracellular calcium is involved in the TIMP-1 basal
and induced production, which suggested ion movements as
a parameter of TIMP-1 regulation.
2. Materials and methods
2.1. Reagents
Reagents used in this work were obtained from the
following sources: IL-10, LPS, Con A, phorbol myristate
acetate (PMA), all trans-retinoic acid (Ret ac), monensin,
ionomycin, BAPTA-AM (Sigma Chemical Co, St Louis,
MO); IL-1h, IL-2, IL-6, TNFa, TGFh (Roche–Boehringer
Mannheim, Meylan, France).
2.2. Cell culture
Six different EBV B lymphocyte cell lines (B95-8 strain
[36]) were cultured in an RPMI-1640 medium supplemented
with 10% (v/v) FBS, 100 U/ml penicillin, 50 Ag/ml kana-
mycin and 50 Ag/ml streptomycin (Gibco BRL, Life Tech-
nologies SARL, Cergy Pontoise, France). The culture was
maintained at 37 jC in a humidified atmosphere containing
5% CO2 and the medium was changed twice weekly.
To study MMP and TIMP expression, FBS was removed
from EBV B lymphocyte culture medium. Cells were
washed three times in 40-ml FBS-free RPMI-1640 medium
and then were grown for different culture times in the same
medium containing 0.2% (w/v) BSA (Roche–Boehringer
Mannheim) and in some experiments a stimulating agent.
Cell viability was monitored by the trypan blue exclusion
method; it was on the order of 90%.
2.3. RT-PCR analysis
Extraction of total RNA from control and stimulated
EBV B lymphocytes by TRIzolk Reagent (Gibco–Life
Technologies) and reverse transcription to cDNA were
performed as previously described [29]. A fragment of
MMP-9 and actin cDNA (838 bp) or a portion of TIMP-1
and glyceraldehyde 3-phosphate dehydrogenase (G3PDH)
cDNA (450 bp) were then amplified simultaneously in the
same tube by PCR, using 2.5 U Taq polymerase (Appligene
Oncor, Illkirch, France) in 100 Al Taq buffer containing 0.2
mM dNTP, 0.25 AM oligonucleotide primers for MMP-9 or
TIMP-1 [29], and 0.125 AM commercial primers (Clontech
Laboratories, Palo Alto, CA) for actin (sense 5V-294–325
bp/antisense 5V-1131–1100 bp) or G3PDH (sense 5V-586–
605 bp/antisense 5V-1037–1018 bp). The PCR protocol was
the same as used before [29]. Aliquots of 4 to 15 Al PCR
products were run together with a scale of DNA ladders
(markers VI, Roche–Boehringer Mannheim) on 1.5% (w/v)
agarose gel containing 1 Ag/ml ethidium bromide. Signal
intensity of target (MMP-9 and TIMP-1) and internal con-
trol (actin and G3PDH) PCR products appearing on the gel
photograph were digitalized by densitometry at 510 nm (CD
60, Desaga, Sarstedt Gruppe). Relative abundance was
calculated as a ratio of MMP-9 to actin or TIMP-1 to
G3PDH signals, as previously done [37].
PCR products were gel-purified and sequenced by
Genome Express Ltd., Grenoble, France.
2.4. Northern blot analysis
Northern blot analysis was carried out using the previ-
ously published method [29]. Briefly, EBV B lymphocyte
total RNA was extracted by the TRIzolk technique and
poly(A) + RNA was purified onto an oligo(dT) cellulose
matrix. After denaturation at 65 jC for 15 min, mRNA was
size-fractionated on a 1% (w/v) agarose–formaldehyde gel,
blotted onto a positive nylon membrane by capillary action
and immobilized by UV cross-linking. The membrane was
then hybridized overnight at 42 jC with a PCR digoxigenin
(DIG)-labeled probe of MMP-9 or TIMP-1 mRNA. After
washing, the detection was performed using anti-digoxige-
nin (Fab) fragments conjugated to alkaline phosphatase
followed by a chemiluminescent reaction (Roche–Boeh-
ringer Mannheim). Signals were detected by exposing the
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blot onto Hyperfilm MP (Amersham Life Science, Buck-
inghamshire, UK). The membrane was then briefly washed
and hybridized again with a DIG-labeled probe of G3PDH
transcript. The mRNA integrity and the size of each charac-
terized mRNA were assessed by visualizing the remaining
28S and 18S ribosomal RNA bands under UV light after
staining the gel with ethidium bromide. Quantitation was
performed by scanning densitometry at 400 nm of the MMP-
9, TIMP-1 and G3PDH bands seen on X-ray films and was
expressed as a ratio MMP-9 or TIMP-1 to G3PDH signals.
2.5. MMP-9 and TIMP-1 production by EBV B lymphocytes
MMP-9 and TIMP-1 were isolated from EBV B lym-
phocyte culture medium as previously published [29].
Briefly, washed cells were cultivated for 18 h in an FBS-
free RPMI medium containing 0.2% BSA and a stimulating
agent. The medium was then withdrawn and cells were
further cultivated in the same medium for 72 h. MMP-9 was
purified using substrate affinity chromatography on gelatin
agarose (Sigma), characterized after Centricon 10 concen-
tration onto a 0.05% (w/v) gelatin zymography and quanti-
tated by scanning densitometry and reference to a purified
MMP-9 standard curve. Free TIMP-1 and MMP-9 com-
plexed TIMP-1 were measured in the culture medium using
a commercial ELISA assay (Amersham Life Science).
TIMP-1 was also investigated inside the cells: EBV B
lymphocytes were sonicated three times for 10 s at 40 W,
the homogenate was centrifuged at 500 g for 10 min and
TIMP-1 was quantitated by ELISA in the supernatant. All
the experiments were standardized by using an equal num-
ber of cells and P values were calculated by the Student’s
paired t test.
2.6. Flow cytometry
EBV B lymphocytes stimulated by 10 ng/ml LPS were
cultured for 18 h with or without (control) 2.5 AMmonensin
and were suspended in PBS at a 3 106 cells/ml concen-
tration. Cells were fixed with 3% (w/v) paraformaldehyde
and 0.25% (v/v) glutaraldehyde and were resuspended in 1
ml PBS containing 1% (w/v) BSA, 0.001% saponin and
10% (v/v) rabbit nonimmune serum, which had been pre-
viously heated for 30 min at 63 jC to reduce nonspecific
binding of antibodies. They were then incubated at 4 jC for
45 min with rabbit polyclonal Ig anti-rTIMP-1 (1:20),
generated with rTIMP-1 (a generous gift from Synergen).
After two washes, a solution of FITC-conjugated goat anti-
rabbit IgG (1:1000) (Immunotech, Marseille, France) was
added to the lymphocytes and after 45 min at 4 jC, cells
were used for flow cytometry. Samples were analyzed on a
FACScan (Becton Dickinson) fitted with an argon ion-laser
at 488 nm. Fluorescence intensity was measured on a
logarithmic scale and the mean fluorescence of the analyzed
cells was calculated using FACScan research software
(Becton Dickinson).
2.7. Intracellular calcium measurement
This method was developed from a previously described
technique [38]. EBV B lymphocytes were incubated for 15
min at 37 jC with 2.5 mM probenecid (Sigma) and 1 mM
fura-2 AM (Sigma) in an RPMI-1640 medium without
phenol red (Gibco–Life Technologies) or any complements
and then resuspended at a 4 106 cells/ml concentration in
the same medium. The fluorescence of the fura-2 AM
(excitation wavelength 340 nm, emission wavelength 505
nm) was measured for 107 cells at 37 jC under slow
magnetic agitation during the entire experiment. After
reaching a plateau, 1 ml of 100 mM MnCl2 was added to
the curve to chelate extracellular fura-2 AM. After 10 s, 2
ml of diethylenetriaminepentaacetic acid (DTPA) (Sigma)
was added to chelate MnCl2. Cells were then lysated by 50
Al of 20% (v/v) Triton X-100. Fura-2 AM nonligated
calcium was chelated by 25 Al of 0.5 M EGTA and the
pH was finally neutralized with 25 Al of 1 M Tris. Intra-
cellular calcium concentration was determined using the
Fig. 1. TIMP-1 and MMP-9 mRNA characterization by RT-PCR (A) and by
Northern blot (B) analysis. Total RNA was extracted from unstimulated
EBV B lymphocytes cultivated in an RMPI medium containing 10% FBS.
(A) mRNA was reverse transcribed using an oligo(dT) primer and two
double PCRs were performed. PCRs with primers for MMP-9 and actin
(lane 1) or TIMP-1 and G3PDH (lane 2) yielded amplification products of
the expected sizes of 277 bp (MMP-9) and 838 bp (actin), or 769 bp
(TIMP-1) and 450 bp (G3PDH). (B) mRNAwas purified onto an oligo(dT)
cellulose matrix, then loaded on an agarose– formaldehyde gel and blotted
onto a nylon membrane. Total mRNA of MMP-9, TIMP-1 and G3PDH
were characterized with specific digoxigenin-labeled probes. The figure is a
representative example of at least 10 experiments.
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fura-2 AM Kd (224 nM), the baseline fluorescence and the
fluorescence after cell lysis and calcium chelation by EGTA.
3. Results
3.1. Expression of TIMP-1 and MMP-9 transcripts by EBV
B lymphocytes
The capacity of EBV B lymphocytes to express TIMP-1
and MMP-9 mRNA was studied using RT-PCR and North-
ern blot. Firstly, total RNA was reverse transcribed to
cDNA. Then a 769-bp portion of TIMP-1 transcript and a
277-bp fragment of MMP-9 cDNA were amplified by the
Taq polymerase (Fig. 1A). G3PDH or actin cDNA were
used as internal controls. The sequencing of each PCR
product showed, respectively, 99.3% (TIMP-1) and 99.5%
(MMP-9) homology with the published sequences [39,40].
No PCR products were characterized without RT (data not
shown).
The entire mRNA of TIMP-1 and MMP-9 was also
characterized by Northern blot analysis, using digoxige-
nin-labeled probes (Fig. 1B). The size of each mRNA was
estimated using the 18S and 28S ribosomal RNA. Both
mRNAs were isolated at the size previously published
[39,40], i.e. approximately 810 bp for the TIMP-1 mRNA
and 2300 bp for the MMP-9 transcript. A second hybrid-
ization of the positive nylon membrane was then performed
with a G3PDH cDNA probe.
Quantification of PCR products and Northern blot-char-
acterized total mRNA of TIMP-1 and MMP-9 was per-
formed by densitometric scanning of each signal. Results
Table 1
Regulation of TIMP-1 transcription and protein synthesis in EBV B lymphocytes
Stimulating agenta RT-PCR Northern blot Proteins
8 h 14 h 24 h 18 h 72 h
Control 100F 1 (9) 100F 2 (8) 100 (4) 100F 73 (6) 100F 32 (6)
IL-1hb 105F 2 (3) 91F 3 (3) NDc 66F 15 (4) 131F 37 (5)
IL-2 102F 2 (3) 92F 7 (3) ND 163F 37 (4) 138F 34 (4)
IL-6 97F 5 (3) 97F 2 (3) ND 143F 33 (4) 164F 38 (4)
IL-10 110F 2 (3) 117F 2 (3) ND 122F 22 (4) 179F 42 (4) *
TNFa 110F 3 (3) 77F 0 (3) ND 322F 89 (4) 219F 50 (4)
TGFh 93F 2 (3) 79F 3 (3) 151F 91 (5) 336F 40 (3) * 225F 53 (3) *
LPS 85F 6 (4) 85F 4 (4) 107F 24 (3) 709F 138 (9) * 292F 52 (5) *
Con A 80F 2 (3) 77F 2 (3) ND 125F 44 (5) 35F 9 (3)
PMA 73F 1 (3) 72F 1 (3) 97F 8 (3) 859F 258 (5) * 525F 122 (4) *
Ret ac 74F 2 (3) 71F1 (3) 332F 68 (4) * , d 309F 107 (5) 335F 77 (5) *
a Concentration used are 1 ng/ml IL-1h, 25 ng/ml IL-2, 10 ng/ml IL-6, 20 ng/ml IL-10, 20 ng/ml TNFa, 1 ng/ml TGFh, 10 ng/ml LPS, 1 Ag/ml Con A, 0.5
nM PMA and 10 AM retinoic acid.
b Each value was reported to the value 100 of unstimulated cells (control) and represents a meanF S.E. (number of experiments).
c ND: not determined.
d P values were calculated by Student’s paired t test.
* P< 0.05 (stimulation versus control).
Table 2
Regulation of MMP-9 transcription and protein synthesis in EBV B lymphocytes
Stimulating agenta RT-PCR Northern blot Proteins
8 h 14 h 24 h 18 h 72 h
Control 100 (15) 100 (10) 100 (10) 100F 6 (10) 100F 16 (5)
IL-1hb 203F 23 (4) * , c ND ND 87F 9 (3) 239F 47 (5) *
IL-2 270F 9 (3) * 214F 24 (6) * ND 27F 13 (3) * 56F 9 (5)
IL-6 NDd 75F 4 (5) ND 47F 23 (3) * 50F 12 (4)
IL-10 154F 5 (3) * ND ND 67F 13 (4) * 100F 22 (4)
TNFa ND 162F 11 (9) * ND 27F 14 (3) 22F 7 (5) *
TGFh 142F 12 (5) * 103F 7 (9) 149F 47 (7) * 0 (3) * 0 (3) *
LPS 382F 13 (5) * 181F13 (5) * 213F 39 (7) * 393F 24 (6) * 244F 43 (6)
Con A 272F 7 (4) * 151F18 (4) * 228F 29 (7) * 507F 67 (3) * 300F 62 (4)
PMA 273F 12 (4) * 113F 8 (4) * 134F 17 (8) 234F 29 (12) * ND
Ret ac 379F 16 (4) * 254F 22 (4) * 205F 30 (5) * 173F 37 (3) ND
a Concentrations used are detailed in Table 1.
b Each value was reported to the value 100 of unstimulated cells (control) and represents a meanF S.E. (number of experiments).
c P values were calculated by Student’s paired t test.
d ND: not determined.
* P < 0.05 (stimulation versus control).
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are expressed as a ratio TIMP-1 or MMP-9 to G3PDH or
actin, which allows estimation of the abundance of TIMP-1
and MMP-9 mRNA in response to the different agents
(Tables 1 and 2).
3.2. Regulation of TIMP-1 versus MMP-9 expression by
EBV B lymphocytes
TIMP-1 and MMP-9 synthesis by EBV B cells was
investigated at two levels: firstly at the transcription level,
by scanning PCR products and Northern blot-characterized
mRNA, and then at the protein level. TIMP-1 was quantified
by ELISA and MMP-9 was analyzed by zymography fol-
lowed by a densitometric quantification [29]. We analyzed
mRNA after 8 and 14 h for RT-PCR experiments and 24 h for
Northern blot analysis. Proteins were measured in an 18-h
FBS-free medium containing a stimulating agent and a
continuing 72-h identical medium. The optimal dose of most
agents has been previously determined by studying the effect
of at least three concentrations (data not shown). Results are
reported in Tables 1 and 2 and expressed as the percentage of
the control values (mRNA or protein).
Concerning TIMP-1, the results of all PCR reactions
showed total independence of mRNA expression whatever
stimulating agent was used. Only retinoic acid significantly
induced the amount of TIMP-1 transcript, as determined by
Northern blot (Table 1).
In contrast to TIMP-1, the majority of the tested medi-
ators significantly induced the MMP-9 transcript synthesis
(Table 2). IL-1h, IL-2, IL-10, TNFa, LPS, Con A, PMA and
retinoic acid increased the amount of mRNA after 8 and/or
14 h of culture, whereas the stimulation effect of TGFh
decreased after 14 h of culture. The significant induction of
MMP-9 mRNA by TGFh, LPS, Con A and retinoic acid
was confirmed by Northern blot analysis (Table 2).
The study on TIMP-1 and MMP-9 phenotypic expression
investigated not only mRNA transcription but also protein
synthesis. Under unstimulated conditions, TIMP-1 produc-
tion by 107 EBV B lymphocytes fluctuated between 2 and
21 ng depending on the EBV cell line after 18 h of culture in
an FBS-free medium. About 0.15 ng of MMP-9 was
produced by these cells during the same period. After
another 72 h of culture, TIMP-1 production was close to
38 ng, whereas MMP-9 synthesis increased to 0.18 ng. We
had previously shown that all MMP-9 produced was
secreted outside of the cells [29].
As transcript synthesis, TIMP-1 protein expression is
barely influenced by extracellular mediators. Nevertheless,
some ligands were shown to strongly up-regulate the
inhibitor synthesis (Table 1). TGFh, LPS and PMA
increased TIMP-1 production after 18 h of culture and an
additional 72 h of incubation. The increased TIMP-1 syn-
thesis observed with retinoic acid and IL-10 was only
significant after 90 h of culture with these mediators. No
other agents induced any significant effect on TIMP-1
expression.
Concerning MMP-9, basal expression was affected by
exposure of EBV B lymphocytes to different mediators
(Table 2). Increased levels of secreted MMP-9 were
observed after 18 h of culture of the cells with PMA, LPS
and Con A: MMP-9 basal production was increased two-
fold, threefold and fivefold, respectively, in agreement with
the MMP-9 mRNA elevated level previously measured
(multiplicative factor of 2.7, 3.8 and 2.7 determined by
semi-quantitative RT-PCR). MMP-9 expression was also
increased by IL-1h but required at least 30 h to develop
[29]. On the other hand, the enzyme production was
decreased by IL-2, IL-6, IL-10 and TNFa and was totally
abolished by TGFh. Finally, retinoic acid failed to signifi-
Fig. 2. Kinetics of MMP-9 and TIMP-1 synthesis by EBV B lymphocytes
in the presence of LPS (A), Con A (B) and PMA (C). Cells were cultivated
in an FBS-free RPMI medium containing 0.2% BSA and 10 ng/ml LPS (A),
1 Ag/ml Con A (B) or 0.5 nM PMA (C). Medium was withdrawn after
different culture times; TIMP-1 was quantified by ELISA and MMP-9 was
analyzed by zymography and quantitated by scanning densitometry.
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cantly up- or down-regulate MMP-9 production, whereas it
stimulated mRNA synthesis. The discrepancies between
mRNA abundance and protein level suggest a posttranscrip-
tional regulation of MMP-9 expression.
Among all cytokines, growth factors and other tested
mediators, LPS, Con A and PMAwere the three agents that
exerted the strongest stimulation effect on TIMP-1 and/or
MMP-9 synthesis. The production kinetics of TIMP-1 and
MMP-9 in response to these agents was then examined (Fig.
2). TIMP-1 synthesis differed depending on the stimulating
ligand: the inhibitor production was dramatically increased
by LPS and PMA during the first hours of culture until the
production reached a plateau, whereas Con A did not exert
any significant stimulative effect on this expression, as was
previously shown (Table 1). Concomitantly LPS, Con A and
PMA strongly induced MMP-9 synthesis (respectively, 7-,
15- and 3-fold) during the first 24 h of culture and then the
enzyme level slowly decreased.
3.3. Effect of monensin on TIMP-1 production and secretion
The expression and secretion mechanisms of TIMP-1
were then investigated using the carboxylic ionophore
monensin. This compound has been reported to alter protein
secretion by its ability to collapse Na + and H + gradients
across intracellular membranes [41]. EBV B lymphocytes
were incubated with the different stimulating agents and 2.5
AM monensin for 18 h (Fig. 3A) and then for an additional
72 h (Fig. 3B); secreted TIMP-1 was measured in the
extracellular medium using ELISA. Treating the cells with
the ionophore strongly decreased and sometimes abolished
TIMP-1 secretion, whatever the stimulating agent and the
culture time.
Fig. 4. Immunolocalization of TIMP-1 in EBV B lymphocytes. LPS-
stimulated cells (3 106) incubated for 18 h with (B) or without (A) 2.5
AMmonensin were suspended in PBS. They were then fixed, permeabilized
and incubated with rabbit anti-TIMP-1 Ig and then with FITC-conjugated
goat anti-rabbit IgG for flow cytometry. The arrow illustrates the
fluorescent shift and the cellular localization of TIMP-1 upon monensin
incubation.
Fig. 3. Quantitative analysis of TIMP-1 secretion by EBV B lymphocytes
after 18 h (A) or 72 h (B) of culture. Cells were cultivated for 18 h in the
presence of a stimulative agent with (hatched) or without (black) monensin.
The medium was then withdrawn and cells were further cultured in the
same conditions for 72 h. TIMP-1 was quantified by ELISA in both media.
The stimulative agents used were 1 ng/ml IL-1h (lane 2), 25 ng/ml IL-2
(lane 3), 10 ng/ml IL-6 (lane 4), 20 ng/ml IL-10 (lane 5), 20 ng/ml TNFa
(lane 6), 1 ng/ml TGFh (lane 7), 10 ng/ml LPS (lane 8), 1 Ag/ml Con A
(lane 9), 0.5 nM PMA (lane 10) and 10 AM retinoic acid (lane 11). Basal
TIMP-1 production from unstimulated EBV B lymphocytes is shown in
lane 1. The error bars represent the S.E. of at least three experiments.
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To investigate the monensin effect on TIMP-1 secretion,
EBV B lymphocytes were fixed after incubation with LPS
alone (control) and monensin for flow cytometry analysis.
The presence of monensin induced a shift in the main
fluorescence peak corresponding to the intracellular TIMP-
1 (arrow) (Fig. 4B), which increased from 11.5 to 41.7,
illustrating that in the presence of monensin, TIMP-1 was
not secreted in the medium and accumulated inside the cells.
Nevertheless, it has been previously shown that mon-
ensin is able to reduce not only protein secretion but also
protein synthesis by 20% in some in vitro culture models
[42]. The intra- and extracellular amount of TIMP-1
secreted by EBV B lymphocytes in response to monensin
was then quantitated by ELISA (Fig. 5). Without monensin,
as previously shown, TIMP-1 was broadly secreted outside
of the cells whether they were unstimulated or cultivated
with LPS. When monensin was added to the culture
medium, TIMP-1 secretion by LPS-stimulated EBV B
lymphocytes was decreased by 80% (Fig. 5, Table 3).
Concurrently, the amount of intracellular TIMP-1 in mon-
ensin-treated cells increased 2.5-fold. Nevertheless, TIMP-1
total production by 107 monensin-cultivated EBV B lym-
phocytes was about 30 ng, whereas untreated cells synthe-
sized and released about 90 ng TIMP-1; this corresponds to
a 66% decrease in TIMP-1 synthesis by monensin-cultured
EBV B cells.
3.4. Importance of calcium in the control process of TIMP-1
synthesis
The role of Ca2 + in TIMP-1 production was investigated
using the specific Ca2 + chelator BAPTA. BAPTA-AM, a
membrane-permeable form of BAPTA, is able to penetrate a
wide variety of cells without affecting their viability and is
hydrolyzed intracellularly by cytosolic esterases to become
active [43]. The intracellular Ca2 + concentration of control
or LPS-stimulated EBV B lymphocytes ranged from 155 to
180 nM (Table 3). When unstimulated cells were incubated
with 20 AM BAPTA-AM for 18 h, the Ca2 + concentration
was reduced to an undetectable level. The simultaneous
measurement of TIMP-1 in the extracellular medium
showed a decreased secretion of 43% (Table 3). No
TIMP-1 accumulation was found inside the cells (data not
shown), suggesting that BAPTA had an effect on protein
synthesis. In the presence of the carboxylic ionophore
ionomycin, which allows calcium influx, 91% basal intra-
cellular Ca2 + concentration and 96% TIMP-1 production,
as measured in the extracellular medium, were recovered.
These results suggest that the decrease in TIMP-1 produc-
tion by BAPTA-AM-cultivated cells was due to an alteration
of intracellular Ca2 + concentration.
Moreover, no modification of cytoplasmic Ca2 + level
was observed in the presence of 2.5 AM monensin, whereas
TIMP-1 concentration strongly decreased compared to the
LPS control level, as previously shown (Fig. 5): the mon-
ensin-induced decrease of extracellular TIMP-1 was inde-
pendent of cytoplasmic Ca2 + concentration.
4. Discussion
The main aim of this study was to describe TIMP-1
regulation mechanisms in EBV B lymphocytes. We first
demonstrated the roughly constitutive expression of the
inhibitor and we then characterized the significant effect
of monensin on TIMP-1 production and secretion. The
results showed the direct involvement of Ca2 + in TIMP-1
basal synthesis by EBV B cells.
Indeed, TIMP-1, first described as an erythroid potenti-
ating factor [12], has also been described as having growth
factor [10] and anti-angiogenic activities [44], and more
recently as acting as an anti-apoptotic factor [14,15] and a
modulator of B cell differentiation [16,17]. Moreover, its
expression has been correlated with differential prognosis in
cancer according to the neoplasm type [45–49]. In partic-
ular, its expression and role was studied in Burkitt’s lym-
Fig. 5. Influence of monensin on TIMP-1 synthesis by EBV B
lymphocytes. Unstimulated and LPS-stimulated cells, with or without 2.5
AM monensin, were cultivated for 18 h. The medium was then withdrawn
and cells were sonicated. TIMP-1 was quantified by ELISA in the
extracellular medium and in the cell lysate. The error bars represent the S.E.
of at least three experiments.
Table 3
Influence of Ca2 + concentration on TIMP-1 production by EBV B
lymphocytes
Culture
conditions
Extracellular TIMP-1
(% control)
Intracellular
[Ca2 + ] (nM)
Controla 100F 73 180F 24
LPS (10 ng/ml) 709F 138 155F 21
LPS +Monb 147F 62 183F 20
BAPTA (20 AM) 57F 3 undetected
BAPTA+ Ionob 96F 28 152F 12
a Each value represents a meanF SE of at least duplicate determinations.
b Monensin (Mon) was used at a 2.5 AM concentration and ionomycine
(Iono) at a concentration of 5 Ag/106 cells.
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phoma, showing an initial growth factor effect on the tumor
followed by an angiogenic inhibition period [50,51]. Under-
standing TIMP-1 regulation would allow better control of
these different activities.
TIMP-1 expression by EBV B lymphocytes was exam-
ined in response to different kinds of mediators that influ-
ence B lymphocyte phenotype (IL-1h, IL-2, IL-6, IL-10,
etc.), EBV B cell proliferation (retinoic acid) [35] or
lymphocyte response in pathological situations (TNFa,
LPS, Con A, etc.). IL-6 also plays a role in EBV-induced
B cell tumorigenesis [33] and IL-10 has anti-angiogenic and
anti-tumorigenic activities on Burkitt’s lymphoma cells [34].
MMP-9 synthesis was also investigated at the same time and
compared to TIMP-1 production. Enzyme transcript and
protein synthesis were shown to be finely regulated: LPS,
Con A and PMA greatly increased MMP-9 production,
whereas other mediators such as IL-2, IL-6, TNFa and
TGFh partially inhibited or totally abolished the enzyme
synthesis. Nevertheless, MMP-9 synthesis was always much
lower than TIMP-1 production whatever stimulating medi-
ator was used, which results in a great MMP-9/TIMP-1
imbalance in favor of the inhibitor. We looked for 14 other
MMPs and TIMPs by RT-PCR; only MMP-7 (matrilysin)
and MMP-16 (membrane type 3 MMP) transcripts were
isolated and both proteins were characterized at a very low
level (data not shown). All these results suggested a function
for EBV B cell TIMP-1 other than an MMP inhibitor, as
was discussed previously [14,24].
As in T lymphocytes [52] and macrophages [53], TIMP-
1 production by EBV B cells is broadly constitutive. We
found that mRNA synthesis was unchanged whatever the
stimulating agent used, and protein synthesis was only
enhanced by a few specific ligands: only IL-10, TGFh,
LPS, PMA and retinoic acid were able to induce TIMP-1
production, as previously described from different sources
[19]. Nevertheless, the response delay to IL-10 and retinoic
acid might result from several gene-expression cascades.
IL-10 was previously shown to greatly increase TIMP-1
synthesis in native B lymphocytes whose basal production
is much lower than in immortalized cells [24]. Moreover,
TIMP-1 synthesis and secretion have also been up-regulated
by this cytokine in other cell types, suggesting an induction
process via an autocrine mechanism [54,55]. Recent data
characterizing a TIMP-1 induction of IL-10 in Burkitt’s
lymphoma cell lines confirmed this hypothesis [17]. Several
in vitro studies reported a correlation of TIMP-1 and IL-10
elevated levels with the high grade of tumors and the poor
outcome of patients [16,17], but both proteins were also
shown to alter tumorigenicity and angiogenesis of Burkitt’s
lymphoma in vitro or in mouse models [34,51]. Prognosis
significance of TIMP-1 and IL-10 needs to be clarified by
clinical studies.
Calcium is known not only to be necessary to metal-
loproteinase activity [1], but also to modulate MMP expres-
sion and/or activation [56–59]. Moreover, synthetic calcium
influx inhibitors were shown to inhibit cancer cell growth
and invasion in vitro [60] and in vivo [61], acting through a
strong decrease in MMP synthesis. The importance of Ca2 +
as a second messenger in signaling pathways was also
described for TIMP-1 induction in Sertoli cells [62]. We
have reported here, for the first time, that Ca2 + is directly
involved in TIMP-1 basal synthesis in EBV B lymphocytes.
The intracellular Ca2 + chelator BAPTA greatly decreased
TIMP-1 production, which is restored by the Ca2 + iono-
phore ionomycin concomitantly with calcium concentration.
TIMP-1 synthesis and secretion were also shown to be
strongly decreased by monensin, a carboxylic ionophore
inhibiting protein extracellular secretion. Basal and induced
productions were affected, which could be explained by a
slow-down of the autocrine loop due to the global decrease
in TIMP-1 synthesis. Down-regulation of TIMP-1 produc-
tion was associated with an accumulation inside the cells, as
was previously described in human endometrium treated
with monensin [63]. Moreover, monensin, which is also
known to raise cytoplasmic calcium in some bovine cells
[64], has no influence on B lymphocyte intracellular Ca2 +
and thus acts at a different level. These two experiments,
both showing a partial inhibition of TIMP-1 synthesis,
brought out the existence of several independent pathways
leading to the inhibitor production.
Our study was done on EBV-immortalized B lympho-
cytes. As disregulation of metalloproteinases and TIMPs
synthesis is implicated in tumor invasion process and meta-
stasis, knowledge of MMP and TIMP expression and
regulation by premalignant lymphoblastoid cell lines is very
relevant. Indeed, in this paper we have shown a broadly
constitutive high expression of TIMP-1 by EBV B cells and
an inducible weak synthesis of MMP-9. These results
contrast with MMP-9/TIMP-1 expression in normal B cells
whose TIMP-1 synthesis is much lower than MMP-9
production [24]. Synthesis of a huge amount of TIMP-1
versus the MMP-9 low production argues in favor of the
preponderant role of the inhibitor in EBV B lymphocyte
physiology. The interesting new findings reported here are
the importance of calcium ions on basal and induced TIMP-
1 production as well as the existence of an autocrine
regulation mechanism. These precise pathways of TIMP-1
synthesis are currently under investigation.
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